Zoetis Appoints New Chief Commercial Officer

Ticker: ZTS · Form: 8-K · Filed: 2024-05-24T00:00:00.000Z

Sentiment: neutral

Topics: executive-appointment, compensation

Related Tickers: ZTS

TL;DR

Zoetis names Michael Smith as new CCO, starting June 3rd. Big pharma shakeup!

AI Summary

On May 20, 2024, Zoetis Inc. announced the appointment of Michael J. Smith as Executive Vice President, Chief Commercial Officer, effective June 3, 2024. Smith will receive an annual base salary of $500,000 and will be eligible for the company's annual incentive plan and long-term equity awards. He previously served as Executive Vice President, U.S. Operations.

Why It Matters

The appointment of a new Chief Commercial Officer can signal a strategic shift in how Zoetis plans to market and sell its animal health products, potentially impacting future revenue growth and market share.

Risk Assessment

Risk Level: low — This filing primarily concerns an executive appointment and compensation, which typically carries a low risk of immediate market impact.

Key Numbers

$500,000 — Annual Base Salary (For the newly appointed Chief Commercial Officer, Michael J. Smith.)

Key Players & Entities

Zoetis Inc. (company) — Registrant
Michael J. Smith (person) — Appointed Executive Vice President, Chief Commercial Officer
June 3, 2024 (date) — Effective date of appointment
$500,000 (dollar_amount) — Annual base salary for Michael J. Smith

FAQ

What is Michael J. Smith's new role at Zoetis Inc.?

Michael J. Smith has been appointed as Executive Vice President, Chief Commercial Officer, effective June 3, 2024.

What is Michael J. Smith's starting salary?

Michael J. Smith will receive an annual base salary of $500,000.

When does Michael J. Smith's appointment become effective?

The appointment of Michael J. Smith is effective June 3, 2024.

What was Michael J. Smith's previous role at Zoetis?

Michael J. Smith previously served as Executive Vice President, U.S. Operations.

What other compensation will Michael J. Smith be eligible for?

Michael J. Smith will be eligible for Zoetis's annual incentive plan and long-term equity awards.

From the Filing

0001555280-24-000262.txt : 20240524 0001555280-24-000262.hdr.sgml : 20240524 20240524071203 ACCESSION NUMBER: 0001555280-24-000262 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240520 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 24980794 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20240520.htm 8-K zts-20240520 0001555280 false 0001555280 2024-05-20 2024-05-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2024 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way Parsippany New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 20, 2024, in connection with Heidi C. Chen’s previously announced separation, Zoetis Inc. (the “Company”) entered into a Letter Agreement (the “Letter Agreement”) with Ms. Chen. The Letter Agreement provides that Ms. Chen will continue employment as a non-corporate officer employee of the Company through July 16, 2024